Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. De Censi
F01*Dose-Dense Adjuvant Chemotherapy, Treatment-Induced Amenorrhea and Overall Survival in Premenopausal Breast Cancer Patients: A Pooled Analysis of the MIG1 and GIM2 Phase 3 Studies
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
Randomised Trial: Survival Benefit and Safety of Adjuvant Dose-Dense Chemotherapy for Node-Positive Breast Cancer
British Journal of Cancer
Cancer Research
Oncology
A Nomogram to Predict the Overall Survival of Breast Cancer Patients and Guide the Postoperative Adjuvant Chemotherapy in China
Cancer Management and Research
Oncology
Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Sedentary Work and the Risk of Breast Cancer in Premenopausal and Postmenopausal Women: A Pooled Analysis of Two Case–control Studies
Occupational and Environmental Medicine
Environmental
Public Health
Occupational Health
The Prosigna Gene Expression Assay and Responsiveness to Adjuvant Cyclophosphamide-Based Chemotherapy in Premenopausal High-Risk Patients With Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Relationship Between Reproductive History, Anthropometrics, Lifestyle Factors, and the Likelihood of Persistent Chemotherapy-Related Amenorrhea in Women With Premenopausal Breast Cancer
Fertility and Sterility
Gynecology
Reproductive Medicine
Obstetrics
Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment
Clinical Drug Investigation
Medicine
Pharmacology
Delivery of Adjuvant Sequential Dose-Dense FEC–Doc to Patients With Breast Cancer Is Feasible, but Dose Reductions and Toxicity Are Dependent on Treatment Sequence
Breast Cancer Research and Treatment
Cancer Research
Oncology
Tamoxifen — No Longer a Golden Standard for Adjuvant Therapy in the Treatment of Premenopausal Patients With Hormone-Sensitive Breast Cancer
Nowotwory
Cancer Research
Oncology
